论文部分内容阅读
在医疗卫生技术应用管理高级研讨会上,多数参会人员认为,对医疗新技术实行“准入”制已势在必行,因为许多新技术如果缺乏技术和管理规范,就有可能对病人造成不必要的损害。军事医学科学院野战输血研究所所长裴雪涛指出,使用干细胞治疗心肌梗死时,如果医师不注意把握治疗时机,不能在病人心梗后合理的治疗时间窗内注射干细胞,或输注干细胞的部位不正确,就可能发生事与愿违的结果,具有多种分化潜能的干细胞可能不分化为心肌细胞,而分化为成纤维细胞,导致瘢痕形成。 对于医院管理者来说,引进和开发新技术既是提高医疗水平的一个方面,但也是一种风险投资,应该如何考虑是否引进某项新技术呢?北京伟益心血管病医院有限公司总经理Griffin具有35年医院管理经验,她认为,医院管理者应该在引进新技术之前
At the seminar on medical and health technology application management, most of the participants believed that it is imperative to implement the “admission” system for new medical technologies, as many new technologies may cause problems for patients if they lack technology and management practices. Unnecessary damage. Wu Xuetao, director of the Institute of Military Blood Transfusion at the Academy of Military Medical Sciences, pointed out that if stem cells are used to treat myocardial infarction, if doctors do not pay attention to the timing of the treatment, stem cells cannot be injected within a reasonable window of time after the patient’s myocardial infarction, or the site of infusion of stem cells is incorrect. The result may be counterproductive. Stem cells with multiple differentiation potentials may not differentiate into cardiomyocytes but differentiate into fibroblasts, leading to scar formation. For hospital managers, the introduction and development of new technologies is not only an aspect of improving the medical level, but also a kind of venture investment. How should we consider whether to introduce a new technology? General Manager of Beijing Weiyi Cardiovascular Hospital Co., Ltd. Griffin With 35 years of hospital management experience, she believes that hospital managers should be